Fig. 2From: Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancerTime-dependent receiver operator characteristics curves for HI50% (A); Kaplan–Meier curves of PFS stratified by HI50% (B)Back to article page